Morgan Stanley Maintains Equal-Weight on PPL, Lowers Price Target to $33

Morgan Stanley analyst Stephen Byrd maintains PPL (NYSE:PPL) with a Equal-Weight and lowers the price target from $34 to $33.

byBenzinga Newsdesk

September 17, 2021

1 minute read

Morgan Stanley analyst Stephen Byrd maintains PPL (NYSE:PPL) with a Equal-Weight and lowers the price target from $34 to $33.

Piper Sandler Maintains Overweight on Wells Fargo, Raises Price Target to $49

By Benzinga Newsdesk

Today, 5:04 AM

Piper Sandler analyst Scott Siefers maintains Wells Fargo (NYSE:WFC) with a Overweight and raises the price target from $48 to $49.

WFC

Ayurcann FY 2022 Net Revenue Grows 23%, What About Net Loss?

By Vuk Zdinjak

Today, 5:04 AM

Ayurcann Holdings Corp. (OTCQB:AYURF) (CSE: AYUR) (FSE:3ZQ0), released its financial and operational results for the year ended June 30, 2022, revealing net revenue increased to CA$9.4 million ($6.9 million), a 23% increase compared to CA$7.6 million in 2021.

AYURF

News

Twilio Segment Unveils New CDP Developer Toolkit

By Benzinga Newsdesk

Today, 5:04 AM

Twilio Segment (NYSE:TWLO), the world's #1 Customer Data Platform (CDP), today unveiled its Developer Toolkit, a unique set of developer tools that gives companies unprecedented flexibility to

TWLO

Merck, Eisai Report Positive CHMP Opinion For KEYTRUDA Plus LENVIMA In 2 Different Types Of Cancer

By Benzinga Newsdesk

Today, 5:04 AM

Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib in CLEAR/KEYNOTE-581

MRK

Morgan Stanley Maintains Equal-Weight on PPL, Lowers Price Target to $33

Related Posts

Piper Sandler Maintains Overweight on Wells Fargo, Raises Price Target to $49

Ayurcann FY 2022 Net Revenue Grows 23%, What About Net Loss?

Twilio Segment Unveils New CDP Developer Toolkit

Merck, Eisai Report Positive CHMP Opinion For KEYTRUDA Plus LENVIMA In 2 Different Types Of Cancer